Abbvie Inc (ABBV): Registrational phase-2 Venetoclax trial...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	826
Posts	119569
Boards Moderated	14
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 235

Wednesday, 08/12/2015 9:48:24 AM

Wednesday, August 12, 2015 9:48:24 AM

Registrational phase-2 Venetoclax trial succeeds in CLL:

http://finance.yahoo.com/news/phase-2-study-venetoclax-patients-123000896.html

AbbVie…today announced that a Phase 2 trial of its investigational medicine venetoclax met its primary endpoint of achieving overall response rates in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion, according to an independent review analysis.

…Data from this study will be presented at an upcoming medical conference and will serve as the pivotal registration data for applications to the FDA, EMA and other health authorities. The safety profile was similar to previous studies and no unexpected safety signals were reported for venetoclax.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”